Safety concerns about dosing of Pfizer Inc.’s COVID-19 oral treatment Paxlovid in renally impaired patients, the two-drug combination’s packaging configuration and a host of potential drug-drug interactions resulted in a US Food and Drug Administration emergency use authorization with complex prescribing and dispensing instructions for some patients.
Reduced dosing for patients with moderate renal impairment will require pharmacists to manually make changes to the Paxlovid packaging, creating...